Both in Biotechnology
Prime Medicine vs Monte Rosa Therapeutics
Over the past year PRME returned +15.6% and GLUE returned −9.8%; their daily moves had a correlation of 0.27.
PRME +15.6% GLUE −9.8%Growth of $1, one year, split-adjusted
| Metric | PRME | GLUE |
|---|---|---|
| Price | $4.97 | $10.82 |
| Market cap | $901.4M | $923.1M |
| Today | +9.23% | +3.94% |
| 1 month | +42.0% | +9.6% |
| 6 months | +45.7% | −46.9% |
| Year to date | +43.2% | −31.0% |
| 1 year | +9.0% | −10.4% |
| Revenue growth (YoY) | +3.5% | −61.3% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −3649.0% | −483.9% |
| P/E (TTM) | — | — |
| Price / sales | 221.3× | 32.1× |
| Net cash | $95.1M | $621.1M |
| Dividend yield | — | — |
| Volatility (60d) | 112.8% | 53.3% |
| Short % of float | 34.4% | 41.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).